Cargando…
SAT672 Dulaglutide Might Reduce Visceral Fat In Patients With Metabolic Syndrome
Disclosure: Y. Kim: None. Liraglutide was shown to reduce visceral fat irrespective of T2DM status. However, due to cost and insurance coverage, dulaglutide has been prescribed more often than liraglutide in the clinical setting. This retrospective study aimed to evaluate the effect of dulaglutide o...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553872/ http://dx.doi.org/10.1210/jendso/bvad114.120 |